Search

Your search keyword '"Merck KGaA -- Joint ventures"' showing total 22 results
Start Over Descriptor "Merck KGaA -- Joint ventures"
22 results on '"Merck KGaA -- Joint ventures"'

1. Agilyx AS: MilliporeSigma Joins Cyclyx as Founding Member

Subjects
Merck KGaA -- Joint ventures, Exxon Mobil Corp. -- Joint ventures, Petroleum industry -- Joint ventures, Product life cycle, Consortia, Green products, Pharmaceutical industry -- Joint ventures, Consortium, Company joint venture, General interest, News, opinion and commentary
Abstract

Oslo: Agilyx AS has issued the following news release: Cyclyx International, a consortium feedstock management joint venture founded by Agilyx and ExxonMobil, has announced MilliporeSigma has joined the consortium as [...]

Published
2021

2. P&G: Merck KGAA deal 'improves upon' PGT Healthcare JV with Teva

Subjects
Merck KGaA -- Joint ventures, Teva Pharmaceutical Industries Ltd. -- Joint ventures, Procter & Gamble Co. -- Joint ventures, Pharmaceutical industry -- Joint ventures, Health care reform, Cleaning agents industry -- Joint ventures, Company joint venture, Business, News, opinion and commentary
Abstract

P&G (PG) says the Merck KGaA Consumer Health (MKGAY) acquisition replaces and improves upon the highly successful PGT Healthcare joint venture P&G had with Teva Pharmaceutical Industries (TEVA), which will [...]

Published
2018

3. P&G Acquires the Consumer Health Business of Merck KGaA, Darmstadt, Germany

Subjects
Merck KGaA -- Joint ventures, Procter & Gamble Co. -- Joint ventures, Brand equity, Pharmaceutical industry -- Joint ventures, Cleaning agents industry -- Joint ventures, Company joint venture, Business, Business, international
Abstract

Strengthens Portfolio, Category Footprint in Top 15 Global OTC Markets Replaces and Improves Upon Successful PGT Healthcare Joint Venture CINCINNATI -- The Procter & Gamble Company (NYSE:PG) today announced it [...]

Published
2018

4. P&G vitamin deal; Amazon's Prime number; Qualcomm's Chinese hurdle

Subjects
Semiconductor industry, Telecommunications services industry, Company joint venture, Dietary supplements industry -- Joint ventures, Cable television broadcasting industry -- Joint ventures, Vitamins, Semiconductor industry -- Joint ventures, Dietary supplements, Soap and cleaning agents industry -- Joint ventures, Telecommunications services industry -- Joint ventures, Video production companies -- Joint ventures, Pharmaceutical industry -- Joint ventures, Communications industry -- Joint ventures, Merck KGaA -- Joint ventures, AT&T Inc. -- Joint ventures, QUALCOMM Inc. -- Joint ventures, Warner Media L.L.C. -- Joint ventures, Cable News Network -- Joint ventures, Procter & Gamble Co. -- Joint ventures, Teva Pharmaceutical Industries Ltd. -- Joint ventures
Abstract

Byline: Ivana KottasovÈí LONDON (CNNMoney) -- 1. Vitamin deal: Procter & Gamble announced Thursday it is buying the consumer health business of German pharmaceutical company Merck KGaA for about é¼3.4 [...]

Published
2018

5. GSK buys out Novartis in $13 billion consumer healthcare shake-up

Subjects
Merck KGaA -- Joint ventures, Pfizer Inc. -- Joint ventures, Novartis AG -- Joint ventures, Pharmaceutical industry -- Joint ventures, Company joint venture, News, opinion and commentary
Abstract

GlaxoSmithKline Headquarters in London. FILE PHOTO | NMG GlaxoSmithKline is buying Novartis out of their consumer healthcare joint venture for $13 billion, taking full control of products including Sensodyne toothpaste, [...]

Published
2018

6. Profile of Matthew W. Emmens CEO of Bristol-Myers Squibb Co

Subjects
Merck & Company Inc. -- Joint ventures, Merck KGaA -- Joint ventures, Shire PLC -- Joint ventures, Bristol-Myers Squibb Co. -- Joint ventures, Chief executive officers, Pharmaceutical industry -- Joint ventures, Company joint venture, General interest, News, opinion and commentary
Abstract

New York: Following is the Profile of Matthew W. Emmens CEO of Bristol-Myers Squibb Co: Matthew Emmens, age 65, brings to the Board more than 40 years of experience in [...]

Published
2017

7. Syntropy to Unlock the Value of Scientific Data in Fight to End Cancer

Subjects
Merck KGaA -- Joint ventures, Palantir Technologies Inc. -- Joint ventures, Joint ventures, Company joint venture, Pharmaceutical industry -- Joint ventures, Software industry -- Joint ventures, Cancer, Research institutes, Brand names, High technology industry, Biotechnology, Scientists, Technology
Abstract

2018 DEC 3 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Business Week -- Merck KGaA, Darmstadt, Germany, a leading science and technology company, and software company Palantir [...]

Published
2018

8. Merck and Praxair Dissolve Electronic Chemicals Alliance

Author

HUME, CLAUDIA

Subjects
Merck KGaA -- Joint ventures, Praxair (Minot, South Dakota) -- Joint ventures, Specialty chemicals industry -- Joint ventures, Business, Chemicals, plastics and rubber industries, Company joint venture, Joint ventures
Abstract

MERCK KGAA (DARMSTADT, GERMANY) and Praxair have dissolved their two-year-old distribution and research alliance for electronic chemicals. 'The deal was just not delivering the results we'd hoped for,' says Merck. [...]

Published
2001

9. * Merck Quits JV

Subjects
Merck KGaA -- Joint ventures, Pesticides industry -- Joint ventures, Herbicides -- Joint ventures, Chemical industry -- Joint ventures, Chemicals, Business, Chemicals, plastics and rubber industries, Company joint venture, Joint ventures
Abstract

Merck KGaA (Darmstadt) has agreed to sell its 50% stake in its DM800- million ($416 million)/year contrast medium joint venture to partner Bracco (Milan). Bracco will pay Merck DM1.7 billion [...]

Published
1999

10. Merck KGaA joins the DiViNe Project

Subjects
Merck KGaA -- Joint ventures, Joint ventures, Company joint venture, Pharmaceutical industry -- Joint ventures
Abstract

Merck KGaA Darmstadt, Germany announced that the company has joined the DiViNe Project, a European consortium of six companies to address challenges facing the development, manufacture, and delivery of vaccines. [...]

Published
2016

11. Compugen, Merck Serono set up biomarkers JV

Subjects
Merck KGaA -- Joint ventures, Compugen Ltd. -- Joint ventures, Biotechnology industry -- Joint ventures, Biological markers, Pharmaceutical industry -- Joint ventures, Company joint venture, Business, General interest, Business, regional
Abstract

June 25--Compugen Ltd. (Nasdaq: CGEN; TASE: CGEN) and Germany's Merck KGaA unit Merck Serono have established a joint venture, Neviah Genomics, for the discovery and development of novel biomarkers for [...]

Published
2012

12. Germany's Merck seeks partnerships

Author

Oyama, David I.

Subjects
Merck KGAA -- Joint ventures, Biovation Inc. -- Mergers, acquisitions and divestments, Pharmaceutical industry -- Joint ventures, Biotechnology industry -- Mergers, acquisitions and divestments, Business, Business, general
Published
2000

13. M&A Navigator: Deal pipeline - 9 January

Subjects
Merck KGaA -- Joint ventures, Shell PLC -- Joint ventures, Scientific Games Corp. -- Joint ventures, American Financial Group Inc. -- Joint ventures, Pochin's PLC -- Joint ventures, Food processing machinery industry -- Joint ventures, Holding companies, Petroleum industry -- Joint ventures, Commodity futures, Property and casualty insurance industry -- Joint ventures, Pharmaceutical industry -- Joint ventures, Company joint venture, Business, general
Abstract

MANews-(C)2009-2014 The following is a list of deals covered in detail by M&A Navigator this week: - TPG, MANAGEMENT ACQUIRE RESTAURANT OPERATOR PJ UNITED TPG Growth, part of US-based buyout [...]

Published
2014

14. M&A Navigator: Deal pipeline - 9 January

Subjects
Merck KGaA -- Joint ventures, Scientific Games Corp. -- Joint ventures, Shell PLC -- Joint ventures, American Financial Group Inc. -- Joint ventures, Pochin's PLC -- Joint ventures, Holding companies, Food processing machinery industry -- Joint ventures, Petroleum industry -- Joint ventures, Commodity futures, Property and casualty insurance industry -- Joint ventures, Pharmaceutical industry -- Joint ventures, Company joint venture, Business
Abstract

M2 EQUITYBITES-January 9, 2014-M&A Navigator: Deal pipeline - 9 January (C)2014 M2 COMMUNICATIONS http://www.m2.com The following is a list of deals covered in detail by M&A Navigator this week: - [...]

Published
2014

15. Quick movement in development

Subjects
Merck KGAA -- Joint ventures, Merck KGAA -- Product development, Takeda Pharmaceutical Company Ltd. -- Joint ventures, Takeda Pharmaceutical Company Ltd. -- Product development, Chemical industry -- Joint ventures, Chemical industry -- Product development, Herbicides -- Joint ventures, Herbicides -- Product development, Pesticides industry -- Joint ventures, Pesticides industry -- Product development, Pharmaceutical industry -- Joint ventures, Pharmaceutical industry -- Product development, Antibodies -- Product development, Viral antibodies -- Product development, Company joint venture, Business, Pharmaceuticals and cosmetics industries
Abstract

Merck KGaA and Takeda Pharmaceutical Co. will jointly develop and jointly commercialize Merck's matuzumab (EMD 72000), a humanized monoclonal antibody for the treatment of cancer. Merck decided to cooperate with [...]

Published
2005

16. Erbitux first-line for metastatic colorectal cancer?

Subjects
Bristol-Myers Squibb Co. -- Joint ventures, Bristol-Myers Squibb Co. -- Product development, ImClone Systems Inc. -- Joint ventures, ImClone Systems Inc. -- Product development, Merck KGAA -- Joint ventures, Merck KGAA -- Product development, Pharmaceutical industry -- Joint ventures, Pharmaceutical industry -- Product development, Diagnostic reagents industry -- Joint ventures, Diagnostic reagents industry -- Product development, Colorectal cancer -- Care and treatment, Chemical industry -- Product development, Chemical industry -- Joint ventures, Pesticides industry -- Product development, Pesticides industry -- Joint ventures, Herbicides -- Product development, Herbicides -- Joint ventures, Company joint venture, Business, Pharmaceuticals and cosmetics industries, Erbitux (Medication) -- Product development
Abstract

Erbitux, an anti-EGFR monoclonal antibody developed by the joint effort of Imclone Systems, Bristol-Myers Squib and Merck KGaA is expected to be good in the treatment of metastatic colorectal cancer. A report is presented on the new medicine.

Published
2004

17. Merck KGAA

Subjects
Merck KGAA -- Joint ventures, Jerini AG -- Joint ventures, Antineoplastic agents -- Product development, Antimitotic agents -- Product development, Pharmaceutical industry -- Joint ventures, Herbicides -- Joint ventures, Pesticides industry -- Joint ventures, Chemical industry -- Joint ventures, Company joint venture, Business, Chemicals, plastics and rubber industries
Abstract

MERCK KGAA, and fellow German company Jerini AG have agreed to jointly develop small molecule inhibitors against an undisclosed target for oncology. Under the pact, Merck obtains worldwide rights for [...]

Published
2004

18. New hiding effect pigments from Merck and Toyo Aluminum

Subjects
Merck KGAA -- Joint ventures, Merck KGAA -- Product introduction, Toyo Aluminium KK -- Joint ventures, Toyo Aluminium KK -- Product introduction, Aluminum industry -- Joint ventures, Aluminum industry -- Product introduction, Chemical industry -- Joint ventures, Chemical industry -- Product introduction, Company joint venture, Business, Chemicals, plastics and rubber industries
Abstract

* Merck KgaA will launch new hiding effect pigments in a joint development with Toyo Aluminum. The first effect pigment is a reddish orange which is comprised of aluminum flakes [...]

Published
2003

19. M&A Navigator: Deal pipeline - 22 August

Subjects
Merck KGaA -- Joint ventures, Siemens AG -- Joint ventures, Biochrom AG -- Joint ventures, Assicurazioni Generali S.p.A. -- Joint ventures, Insurance industry -- Joint ventures, Electronics industry -- Joint ventures, Pharmaceutical industry -- Joint ventures, Company joint venture, Insurance industry, Electronics industry, Business, general
Abstract

MANews-(C)2009-2012 The following is a list of deals covered in detail by M&A Navigator this week: - UNIVERSAL CAPITAL SIGNS MOU TO BUY 43% IN NB REGENERATION US private equity [...]

Published
2012

20. Autogen patents 30 genes linked to diabetes, obesity

Author

Lawson, Mark

Subjects
Autogen Ltd. -- Intellectual property, Merck KGAA -- Joint ventures, Gene therapy -- Intellectual property, Diabetes -- Research, Obesity -- Research, Biotechnology industry, Business, Business, international
Abstract

SYDNEY, Australia -- Autogen Ltd. said it patented 30 genes identified with diabetes and obesity and is systematically investigating them for possible treatment leads for those diseases. The Melbourne-based company [...]

Published
2001

21. Biomet

Subjects
Biomet Inc. -- Joint ventures -- 00301017, Merck KGAA -- Joint ventures, Surgical equipment and supplies industry -- Joint ventures, Economics, Health care industry, High technology industry
Abstract

Biomet (Warsaw, Indiana) and Merck KGaA (Darmstadt, Germany) have signed an 50/50 joint venture agreement to manufacture, market and sell orthopedic and biomaterials products in Europe under the name Biomet [...]

Published
1998

22. Biomet

Subjects
Biomet Inc. -- Joint ventures -- 00301017, Merck KGAA -- Joint ventures, Medical equipment and supplies industry -- Joint ventures, Economics, Health care industry, High technology industry
Abstract

Biomet (Warsaw, Indiana) has agreed to form a 50/50 venture for orthopedic products in Europe with Merck KGaA (Darmstadt, Germany), a global chemical-pharmaceutical company (not related to Merck & Co. [...]

Published
1998

Catalog

Books, media, physical & digital resources
See catalog results